Prostate cancer · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ipilimumab and RT Variant #01 | — | R 786 153 | 21d | — | — | ~4 | ~R 3 144 612 indirect | — |
Sipuleucel-T monotherapy Variant #01 Partial | — | — | 14d | — | 25.8 mo | 3 | — | 1 |
2 of 2 regimens shown